Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
道彤投资
@daltonventure
以生命科学为根，向硬科技生长
97 articles
Articles
Astribot's Self-Developed Lumo-1 Model: Enabling Robots to Unite Mind and Hand, Entering the Era of Reasoning-Action Loops | DaoTong Family
On December 11, 2025, **Datong Family company Astribot released LUMO-1, a next-generation embodied reasoning VLA model that successfully established a new paradigm for the robot "reasoning-action" closed loop**. Leveraging core technologies including a three-stage training architecture and structured reasoning, the model comprehensively outperformed mainstream baselines on critical tasks such as long-horizon multi-step manipulation and out-of-distribution generalization, enabling responses without programming.
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Dalton Venture's Sun Qi: Unlocking a New Era of Industrial Biotechnology with the Power of "Life Derives All Things," Embracing China's Golden Decade of Biomanufacturing | Dalton Insights
Bio-manufacturing: The "Next Decade" of the Global Industrial Landscape
Wanwu Capital's Bio-Manufacturing Industry Partners Conference Convenes in Shanghai! Shanghai's First Bio-Manufacturing Industry Fund Launches, Partners Discuss the Golden Decade
On the afternoon of October 23, 2025, the "Sheng Yan Wan Wu | Bio-Manufacturing Industry Value Partners Conference," co-hosted by Dalton Venture and OPM Biosciences [688293], was held in Shanghai. Centered on the theme "Sheng Yan Wan Wu" (Life Begets All Things), the conference brought together representatives from government agencies, scholars from research institutes, industry-leading entrepreneurs, fund investors, and ecosystem partners to explore cutting-edge trends in bio-manufacturing and pathways for industrial collaboration.
Vol. 2 The "Efficiency Code" of Bio-Manufacturing: AI Gives Enzymes a 7-Day Iteration Engine | Column · The New Era's Unicorns
The bio-manufacturing industry will undergo structural transformation around 2030.
Vol.1 Finding a Switch for That Chronic Pain You've Endured for So Long | Column · The New Era's Unicorns
In 2025, the global chronic pain treatment market will grow to 500 billion yuan.
Xinyun Medical Closes Tens of Millions of RMB in Series B+ Funding Led by Dalton Venture, Building Innovative Devices and Neuromodulation Solutions for Chronic Pain | Dalton News
AI is emerging as a new engine for breaking through in pain treatment
Triastek Secures China's First 3D-Printed Drug Manufacturing License, Marking a New Era of Digital Innovation in Chinese Pharma | DaoTong Family
In September 2025, **Triastek, a Dalton Venture portfolio company, received the nation's first Pharmaceutical Manufacturing License for 3D-printed drug production issued by the Jiangsu Provincial Medical Products Administration**. This marks the first time that 3D printing pharmaceutical technology in China has achieved compliant, regulated manufacturing. It represents a critical step forward for Triastek in drug R&D and industrialization, as well as another milestone for Dalton Venture's investments in pharmaceutical innovation.
Jinggou Biotech Closes Tens of Millions of Yuan in Series A Funding, Dalton Venture Bets on Synthetic Biology for Nutrition and Health | Dalton News
Recently, emerging Chinese synthetic biology company **Hangzhou Jinggou Biotechnology Co., Ltd. (hereinafter referred to as "Jinggou Bio") announced the completion of a Series A financing round worth tens of millions of RMB, with Dalton Venture participating in the investment.** Proceeds from this round will be primarily directed toward R&D investment and production base capacity building, accelerating the scaled production of high-value-added nutritional health and feed additive products, and advancing the commercialization of green bio-manufacturing.